Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I8FV
|
|||
| Former ID |
DCL001008
|
|||
| Drug Name |
SUN13834
|
|||
| Synonyms |
Trifluperidol; Trisedil; Triperidol; Psychoperidol; Flumoperone; Psicoperidol; Trisedyl; Psicoperidol-R; McN-JR-2498; 749-13-3; Trifluperidolo; Trifluperidolo [DCIT]; R-2498; Trifluperidolo [Italian]; Trifluperidolum [INN-Latin]; NSC 170978; UNII-R8869Q7R8I; Trifluperidol [USAN:INN:BAN]; P 459; BRN 1556208; CHEMBL15023; 1-Butanone, 1-(4-fluorophenyl)-4-(4-hydroxy-4-(3-(trifluoromethyl)phenyl)-1-piperidinyl)-; GPMXUUPHFNMNDH-UHFFFAOYSA-N; R8869Q7R8I; NSC170978; Triperidol (TN)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Gram-positive bacterial infection [ICD-11: 1B74-1G40] | Phase 2 | [1] | |
| Company |
Wyeth
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23F4NO2
|
|||
| Canonical SMILES |
C1CN(CCC1(C2=CC(=CC=C2)C(F)(F)F)O)CCCC(=O)C3=CC=C(C=C3)F
|
|||
| InChI |
1S/C22H23F4NO2/c23-19-8-6-16(7-9-19)20(28)5-2-12-27-13-10-21(29,11-14-27)17-3-1-4-18(15-17)22(24,25)26/h1,3-4,6-9,15,29H,2,5,10-14H2
|
|||
| InChIKey |
GPMXUUPHFNMNDH-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 749-13-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
223527, 443249, 5664288, 8153423, 10534705, 11111838, 14757579, 17396795, 29224606, 48110657, 48416662, 49898313, 50111276, 57322846, 76254799, 85209945, 90340861, 92309312, 103177556, 103977704, 104309605, 124750350, 124881511, 127987556, 134224961, 134339438, 134340647, 134976987, 135709955, 136345614, 136897403, 137144009, 140446711, 162224692, 176484557, 179226165, 198966303, 224017768, 226492421, 250107919
|
|||
| ChEBI ID |
CHEBI:135662
|
|||
| SuperDrug ATC ID |
N05AD02
|
|||
| SuperDrug CAS ID |
cas=000749133
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Chymase (CYM) | Target Info | Modulator | [2] |
| Phosphodiesterase 4 (PDE4) | Target Info | Inhibitor | [3] | |
| KEGG Pathway | Renin-angiotensin system | |||
| Reactome | Activation of Matrix Metalloproteinases | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98. | |||
| REF 2 | Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91. | |||
| REF 3 | Ocular hypotension induced by topical dopaminergic drugs and phosphodiesterase inhibitors. Eur J Pharmacol. 1994 Jun 2;258(1-2):85-94. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.